|
|
Vasogen Inc. - Price Analysis Snapshot
This Report features up to a ten-year record of the equity Price history for Vasogen Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.
Vasogen Inc.. The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure. Celacade technology for the treatment of chronic heart failure in certain countries of the E.U. and LatinAmerica. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.
Not the Report you are looking for? Click here for more browsing options.
Layout and Content of a Typical Report
|
|
|
|
|